MBIO (Mustang Bio, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-27 | Manuel MD Litchman | President, CEO and Interim CFO | F | — | — |
| 2026-01-05 | Fortress Biotech, Inc. | 10%+ Owner | A | — | — |
| 2025-12-30 | Adam J. Chill | Director | Sell | — | — |
| 2025-12-30 | Neil Herskowitz | Director | Sell | — | — |
| 2025-12-30 | David Jin | Director | Buy | — | — |
| 2025-10-01 | Fortress Biotech, Inc. | 10%+ Owner | A | — | — |
| 2025-04-28 | Manuel MD Litchman | President, CEO and Interim CFO | F | — | — |
| 2025-04-02 | Fortress Biotech, Inc. | 10%+ Owner | A | — | — |
| 2024-06-28 | Fortress Biotech, Inc. | 10%+ Owner | A | — | — |
| 2024-06-04 | Manuel MD Litchman | President and CEO | F | — | — |
| 2024-06-04 | Manuel MD Litchman | President and CEO | F | — | — |
| 2024-01-03 | Fortress Biotech, Inc. | 10%+ Owner | A | — | — |
| 2023-07-07 | Adam J. Chill | Director | A | — | — |
| 2023-07-07 | MICHAEL J ZELEFSKY | Director | A | — | — |
| 2023-07-07 | Manuel MD Litchman | President and CEO | A | — | — |
| 2023-07-07 | Neil Herskowitz | Director | A | — | — |
| 2023-07-07 | LINDSAY A MD ROSENWALD | Director | A | — | — |
| 2023-07-07 | MICHAEL S WEISS | Director | A | — | — |
| 2023-04-03 | Adam J. Chill | Director | A | — | — |
| 2023-04-03 | Manuel MD Litchman | Director | MIXED | — | — |
| 2023-04-03 | MICHAEL S WEISS | Director | A | — | — |
| 2023-04-03 | LINDSAY A MD ROSENWALD | Director | MIXED | — | — |
| 2023-04-03 | Neil Herskowitz | Director | A | — | — |
| 2023-04-03 | MICHAEL J ZELEFSKY | Director | A | — | — |
| 2023-01-06 | Fortress Biotech, Inc. | 10%+ Owner | A | — | — |
| 2021-12-16 | Brian Achenbach | SVP, Fin. & Corp. Controller | MIXED | — | — |
| 2021-11-08 | Manuel MD Litchman | President and CEO | Buy | — | — |
| 2021-10-21 | Brian Achenbach | SVP, Fin. & Corp. Controller | Sell | — | — |
| 2021-09-24 | Manuel MD Litchman | President and CEO | A | — | — |
| 2021-09-24 | LINDSAY A MD ROSENWALD | Director | A | — | — |
| 2021-08-05 | Manuel MD Litchman | President and CEO | Buy | — | — |
| 2021-07-08 | Manuel MD Litchman | President and CEO | A | — | — |
| 2021-07-08 | LINDSAY A MD ROSENWALD | Director | A | — | — |
| 2021-07-08 | Neil Herskowitz | Director | A | — | — |
| 2021-07-08 | Adam J. Chill | Director | A | — | — |
| 2021-07-08 | MICHAEL S WEISS | Director | A | — | — |
| 2021-07-08 | MICHAEL J ZELEFSKY | Director | A | — | — |
| 2021-04-29 | Manuel MD Litchman | President and CEO | Sell | — | — |
| 2021-04-16 | Brian Achenbach | SVP, Fin. & Corp. Controller | Sell | — | — |
| 2021-03-15 | Brian Achenbach | SVP, Fin. & Corp. Controller | A | — | — |
| 2021-03-15 | LINDSAY A MD ROSENWALD | Director | A | — | — |
| 2021-03-15 | Manuel MD Litchman | President and CEO | MIXED | — | — |
| 2020-12-22 | LINDSAY A MD ROSENWALD | Director | MIXED | — | — |
| 2020-12-22 | LINDSAY A MD ROSENWALD | Director | A | — | — |
| 2020-12-22 | Manuel MD Litchman | President and CEO | MIXED | — | — |
| 2020-12-15 | LINDSAY A MD ROSENWALD | Director | Buy | — | — |
| 2020-08-19 | LINDSAY A MD ROSENWALD | Director | A | — | — |
| 2020-08-19 | Adam J. Chill | Director | A | — | — |
| 2020-08-19 | MICHAEL J ZELEFSKY | Director | A | — | — |
| 2020-08-19 | Neil Herskowitz | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 536,577 | — |
| — | President, CEO and Interim CFO | 1,615 | — |
| — | Director | 1,210 | — |
| — | Director | 1,060 | — |
| — | Director | 379 | — |
| — | Director | 375 | — |
| — | Director | 286 | — |
| — | SVP, Fin. & Corp. Controller | 199 | — |
| — | Director | 145 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MBIO quote page; the site-wide leaderboard is on the insider transactions hub.